A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety,
tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of
abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate
(gland that makes fluid that aids movement of sperm) cancer (HRPC).